Literature DB >> 12121330

The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060.

A Bagust1, P K Hopkinson, L Maslove, C J Currie.   

Abstract

AIMS/HYPOTHESIS: To predict the incidence and prevalence of Type 2 diabetes in the UK, the trends in the levels of diabetes-related complications, and the associated health care costs for the period 2000-60.
METHODS: An established epidemiological and economic model of the long-term complications and health care costs of Type 2 diabetes was applied to UK population projections from 2000 to 2060. The model was used to calculate the incidence and prevalence of Type 2 diabetes, the caseloads and population burden for diabetes-related complications, and annual NHS health care costs for Type 2 diabetes over this time period.
RESULTS: The total UK population will not increase by more than 3% at any time in the next 60 years. However, the population over 30 will increase by a maximum of 11% by 2030. Due to population ageing, in 2036 there will be approximately 20% more cases of Type 2 diabetes than in 2000. Cases of diabetes-related complications will increase rapidly to peak 20-30% above present levels between 2035 and 2045, before showing a modest decline. The cost of health care for patients with Type 2 diabetes rises by up to 25% during this period, but because of reductions in the economically active age groups, the relative economic burden of the disease can be expected to increase by 40-50%. CONCLUSION/
INTERPRETATION: In the next 30 years Type 2 diabetes will present a serious clinical and financial challenge to the UK NHS.

Entities:  

Mesh:

Year:  2002        PMID: 12121330     DOI: 10.1046/j.1464-5491.19.s4.2.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  30 in total

Review 1.  The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies.

Authors:  Luke W Arnold; Zhiqiang Wang
Journal:  Rev Diabet Stud       Date:  2014-08-10

Review 2.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

3.  Adherence to treatment guidelines and therapeutic regimens: a US claims-based benchmark of a commercial population.

Authors:  C Ron Cantrell; Julie L Priest; Christopher L Cook; Jack Fincham; Steven P Burch
Journal:  Popul Health Manag       Date:  2010-12-13       Impact factor: 2.459

4.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

Review 5.  Economic Impact of Diabetes in Japan.

Authors:  Tatsuhiko Urakami; Remi Kuwabara; Kei Yoshida
Journal:  Curr Diab Rep       Date:  2019-01-16       Impact factor: 4.810

6.  Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach.

Authors:  David S Cobden; Louis W Niessen; Frans Fh Rutten; W Ken Redekop
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

Review 7.  Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Diet-induced obesity causes cerebral vessel remodeling and increases the damage caused by ischemic stroke.

Authors:  Christian Deutsch; Vera Portik-Dobos; Anita D Smith; Adviye Ergul; Anne M Dorrance
Journal:  Microvasc Res       Date:  2009-04-15       Impact factor: 3.514

9.  Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women.

Authors:  Steve E Humphries; David Gable; Jackie A Cooper; Helen Ireland; Jeffrey W Stephens; Steven J Hurel; Ka Wah Li; Jutta Palmen; Michelle A Miller; Francesco P Cappuccio; Robert Elkeles; Ian Godsland; George J Miller; Philippa J Talmud
Journal:  J Mol Med (Berl)       Date:  2006-12       Impact factor: 4.599

10.  Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice.

Authors:  Christof Schöfl; Georg Lübben
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.